Association between Antipsychotic Use and Extrapyramidal Symptoms:
10.11256/jjdi.17.125
- VernacularTitle:非定型および定型抗精神病薬による錐体外路系有害事象の解析
- Author:
Kouichi Hosomi
;
Binawool Park
;
Ryo Inose
;
Mai Fujimoto
;
Mitsutaka Takada
- Publication Type:Journal Article
- Keywords:
atypical antipsychotics;
typical antipsychotics;
extrapyramidal symptoms;
FAERS;
JADER
- From:Japanese Journal of Drug Informatics
2015;17(3):125-132
- CountryJapan
- Language:English
-
Abstract:
Objective: To examine the association between atypical and typical antipsychotics and extrapyramidal symptoms (EPS), we analyzed the US Food and Drug Administration Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report database (JADER) from the Pharmaceuticals and Medical Devices Agency (PMDA).
Methods: A reporting odds ratio was calculated and used to detect spontaneous report signals, with detection defined as a lower limit >1 in a 95% confidence interval. In addition, time to onset and age at onset of EPS were investigated.
Results: Drug-reaction pairs were identified in both FAERS (n=29,017,485) and JADER (n=2,079,653). In analyses of both databases, significant associations were found between atypical and typical antipsychotics and EPS. Atypical antipsychotics cause EPS with a longer duration of therapy compared to typical ones. EPS in patients treated with atypical antipsychotics was observed at a broad range of ages compared to the patients treated with typical ones.
Conclusion: Atypical antipsychotics, like typical ones, may increase the risk of EPS. Because of the longer latency of onset, it may be difficult to find EPS associated with atypical antipsychotics. Therefore, the severe symptom may be developed in patients treated with atypical antipsychotics. The attention should be paid to the EPS in patients of all ages treated with atypical antipsychotics.
